vs
Inotiv, Inc.（NOTV）与OmniAb, Inc.（OABI）财务数据对比。点击上方公司名可切换其他公司
Inotiv, Inc.的季度营收约是OmniAb, Inc.的14.4倍（$120.9M vs $8.4M）。Inotiv, Inc.净利率更高（-23.5% vs -169.3%，领先145.8%）。Inotiv, Inc.同比增速更快（0.8% vs -22.5%）。OmniAb, Inc.自由现金流更多（$-5.7M vs $-10.6M）。过去两年OmniAb, Inc.的营收复合增速更高（48.4% vs 0.8%）
Inotiv公司是一家注册于美国印第安纳州的合同研究组织，总部位于该州拉斐特市。公司设有两大核心业务板块：发现与安全评估业务（DSA）以及研究模型与服务业务（RMS），可为小分子候选药物、生物治疗产品及生物医疗设备提供安全评估、分析、代谢研究、CMC及法规咨询等药物开发与环境科学相关服务。
OmniAb, Inc.是一家跨国生物技术企业，拥有专利转基因动物平台及全流程抗体发现解决方案，与全球制药和生物科技公司合作，加速肿瘤、自身免疫病等刚需医疗领域的全人源治疗抗体开发。
NOTV vs OABI — 直观对比
营收规模更大
NOTV
是对方的14.4倍
$8.4M
营收增速更快
NOTV
高出23.3%
-22.5%
净利率更高
NOTV
高出145.8%
-169.3%
自由现金流更多
OABI
多$4.9M
$-10.6M
两年增速更快
OABI
近两年复合增速
0.8%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $120.9M | $8.4M |
| 净利润 | $-28.4M | $-14.2M |
| 毛利率 | — | — |
| 营业利润率 | -13.5% | -188.2% |
| 净利率 | -23.5% | -169.3% |
| 营收同比 | 0.8% | -22.5% |
| 净利润同比 | -2.7% | -8.5% |
| 每股收益（稀释后） | $-0.83 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NOTVOABI
| Q4 25 | $120.9M | $8.4M | ||
| Q3 25 | $138.1M | $2.2M | ||
| Q2 25 | $130.7M | $3.9M | ||
| Q1 25 | $124.3M | $4.2M | ||
| Q4 24 | $119.9M | $10.8M | ||
| Q3 24 | $130.4M | $4.2M | ||
| Q2 24 | $105.8M | $7.6M | ||
| Q1 24 | $119.0M | $3.8M |
净利润NOTVOABI
| Q4 25 | $-28.4M | $-14.2M | ||
| Q3 25 | $-8.6M | $-16.5M | ||
| Q2 25 | $-17.6M | $-15.9M | ||
| Q1 25 | $-14.9M | $-18.2M | ||
| Q4 24 | $-27.6M | $-13.1M | ||
| Q3 24 | $-18.9M | $-16.4M | ||
| Q2 24 | $-26.1M | $-13.6M | ||
| Q1 24 | $-48.1M | $-19.0M |
营业利润率NOTVOABI
| Q4 25 | -13.5% | -188.2% | ||
| Q3 25 | -4.9% | -810.2% | ||
| Q2 25 | -4.3% | -416.2% | ||
| Q1 25 | -2.4% | -453.6% | ||
| Q4 24 | -12.9% | -147.0% | ||
| Q3 24 | -10.1% | -473.7% | ||
| Q2 24 | -19.6% | -214.1% | ||
| Q1 24 | -36.2% | -593.3% |
净利率NOTVOABI
| Q4 25 | -23.5% | -169.3% | ||
| Q3 25 | -6.2% | -738.1% | ||
| Q2 25 | -13.5% | -407.4% | ||
| Q1 25 | -12.0% | -438.1% | ||
| Q4 24 | -23.0% | -121.0% | ||
| Q3 24 | -14.5% | -392.4% | ||
| Q2 24 | -24.7% | -179.0% | ||
| Q1 24 | -40.4% | -498.8% |
每股收益（稀释后）NOTVOABI
| Q4 25 | $-0.83 | $-0.11 | ||
| Q3 25 | $-0.14 | $-0.14 | ||
| Q2 25 | $-0.51 | $-0.15 | ||
| Q1 25 | $-0.44 | $-0.17 | ||
| Q4 24 | $-1.02 | $-0.13 | ||
| Q3 24 | $-0.73 | $-0.16 | ||
| Q2 24 | $-1.00 | $-0.13 | ||
| Q1 24 | $-1.86 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.7M | $25.5M |
| 总债务越低越好 | $405.8M | — |
| 股东权益账面价值 | $109.0M | $267.0M |
| 总资产 | $734.3M | $300.9M |
| 负债/权益比越低杠杆越低 | 3.72× | — |
8季度趋势，按日历期对齐
现金及短期投资NOTVOABI
| Q4 25 | $12.7M | $25.5M | ||
| Q3 25 | $21.7M | $28.5M | ||
| Q2 25 | $6.2M | $18.3M | ||
| Q1 25 | $19.3M | $10.9M | ||
| Q4 24 | $38.0M | $27.6M | ||
| Q3 24 | $21.4M | $27.2M | ||
| Q2 24 | $14.4M | $20.8M | ||
| Q1 24 | $32.7M | $19.1M |
总债务NOTVOABI
| Q4 25 | $405.8M | — | ||
| Q3 25 | $402.1M | — | ||
| Q2 25 | $396.5M | — | ||
| Q1 25 | $399.5M | — | ||
| Q4 24 | $396.0M | — | ||
| Q3 24 | $393.3M | — | ||
| Q2 24 | $382.4M | — | ||
| Q1 24 | $380.6M | — |
股东权益NOTVOABI
| Q4 25 | $109.0M | $267.0M | ||
| Q3 25 | $136.0M | $277.4M | ||
| Q2 25 | $143.8M | $262.1M | ||
| Q1 25 | $157.7M | $273.5M | ||
| Q4 24 | $169.8M | $287.6M | ||
| Q3 24 | $170.5M | $291.7M | ||
| Q2 24 | $182.1M | $294.2M | ||
| Q1 24 | $207.2M | $301.4M |
总资产NOTVOABI
| Q4 25 | $734.3M | $300.9M | ||
| Q3 25 | $771.1M | $309.7M | ||
| Q2 25 | $759.7M | $295.7M | ||
| Q1 25 | $766.0M | $306.2M | ||
| Q4 24 | $772.9M | $325.6M | ||
| Q3 24 | $781.4M | $331.6M | ||
| Q2 24 | $774.6M | $337.3M | ||
| Q1 24 | $815.4M | $352.6M |
负债/权益比NOTVOABI
| Q4 25 | 3.72× | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | 2.76× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.33× | — | ||
| Q3 24 | 2.31× | — | ||
| Q2 24 | 2.10× | — | ||
| Q1 24 | 1.84× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.4M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $-10.6M | $-5.7M |
| 自由现金流率自由现金流/营收 | -8.8% | -67.8% |
| 资本支出强度资本支出/营收 | 4.3% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-28.7M | $-37.0M |
8季度趋势，按日历期对齐
经营现金流NOTVOABI
| Q4 25 | $-5.4M | $-5.7M | ||
| Q3 25 | $14.3M | $-9.8M | ||
| Q2 25 | $-7.4M | $-5.1M | ||
| Q1 25 | $-12.8M | $-15.9M | ||
| Q4 24 | $-4.5M | $-3.9M | ||
| Q3 24 | $-2.4M | $-6.6M | ||
| Q2 24 | $-14.8M | $-12.2M | ||
| Q1 24 | $16.9M | $-17.0M |
自由现金流NOTVOABI
| Q4 25 | $-10.6M | $-5.7M | ||
| Q3 25 | $11.6M | $-9.9M | ||
| Q2 25 | $-11.5M | $-5.3M | ||
| Q1 25 | $-18.3M | $-16.1M | ||
| Q4 24 | $-9.0M | $-3.9M | ||
| Q3 24 | $-7.7M | $-6.7M | ||
| Q2 24 | $-19.2M | $-12.9M | ||
| Q1 24 | $9.9M | $-18.0M |
自由现金流率NOTVOABI
| Q4 25 | -8.8% | -67.8% | ||
| Q3 25 | 8.4% | -444.2% | ||
| Q2 25 | -8.8% | -136.3% | ||
| Q1 25 | -14.7% | -387.1% | ||
| Q4 24 | -7.5% | -36.3% | ||
| Q3 24 | -5.9% | -161.3% | ||
| Q2 24 | -18.2% | -169.9% | ||
| Q1 24 | 8.3% | -472.5% |
资本支出强度NOTVOABI
| Q4 25 | 4.3% | 0.1% | ||
| Q3 25 | 1.9% | 8.1% | ||
| Q2 25 | 3.1% | 4.2% | ||
| Q1 25 | 4.4% | 5.0% | ||
| Q4 24 | 3.7% | 0.4% | ||
| Q3 24 | 4.1% | 3.6% | ||
| Q2 24 | 4.2% | 9.9% | ||
| Q1 24 | 5.9% | 24.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOTV
| Research Models And Services Segment | $72.9M | 60% |
| Discovery And Safety Assessment Segment | $48.0M | 40% |
OABI
暂无分部数据
